Publication: FHL2: A scaffold protein of carcinogenesis, tumour-stroma interactions and treatment response
Authors
Verset, Laurine ; Feys, Lynn ; Trépant, Anne-Laure ; De Wever, Olivier ; Demetter, Pieter
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-709
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Four-and-a-half LIM-domain protein 2
(FHL2) is a multifunctional scaffolding protein
regulating signalling cascades and gene transcription. It
shuttles between focal adhesions and the nucleus where
it signals through direct interaction with a number of
proteins including β-catenin. The multiplicity of
molecular pathways affected by FHL2 suggests an
important role in several physiological and pathological
events. The function of FHL2 in cancer is particularly
intriguing, since it may act as an oncoprotein or as a
tumour suppressor in a tissue-dependent fashion.
In this review we present the current knowledge on
the role of FHL2 in carcinogenesis, with emphasis on the
digestive tract. We discuss the overexpression of FHL2
in colorectal, gastric and pancreatic cancer, the
downregulation in hepatocellular carcinoma and the role
of FHL2 in epithelial-mesenchymal transition. We
briefly look at the potential role of FHL2 in the tumoural
microenvironment and discuss how FHL2 expression
and function might influence cancer treatment. Before
implementation of FHL2 as a biomarker by pathologists,
antibody validation should, however, be carried out.
publication.page.subject
Citation
Histology and histopathology: Vol.31, nº5 (2016)
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/